Thank you for having me. My name is David Platt, and I will present Bioxytran. I'm the CEO of the company. Let's start. It's a company about complex carbohydrates, chemistry. For some reason, my slide... Okay. It's a public company, and symbol BIXT. And we're dealing with three main problem, which is in virology, in stroke, early stroke, and cancer metastasis. I will concentrate today in the first problem that we work on. Right now, in virology or when you have infection, there is no very quick treatment, so we're trying to make. We're developing a quick treatment for as an antiviral. The second, the company also work on a early stage of stroke, how to deliver oxygen. And the last one is in cancer metastasis. All these problems, we develop drugs based on polysaccharides. So in the viral infection, as I'm talking about early stage of a viral infection, there's no quick treatment, and what we identified is a drug that works against COVID-19, influenza, shingles, long COVID, conjunctivitis, it's a viral of the eyes, the eye, and the RSV. Those are the virus that we identified that chemistry works against. If you look on the reason or the mechanism, how we do that, you can see that all viruses, we identified that all viruses, there are 2,800 known today, has a galectin receptor on the surface. Galectins are on the surface of the virus. The galectins are protein that recognize carbohydrate. They exist in all cells, but the Galectins are unique, has a unique feature or unique like a key, and they're sitting on the on the top of the, on the spike protein, on the surface of of viruses. And what we do, we develop a mechanism or the, the drug to block those Galectins. And we call him Galectin antagonist, which it's like a key and a lock. So the lock is the Galectin, and the key is the Galectin antagonist. When it bind to the Galectin, it basically block it from operating what it or their function. We block the function of the, of the Galectin by adding or connecting the Galectin antagonist to the Galectin. About the galectin, 40 years ago, I was the one who actually cloned the gene, not clone, expressed the gene for galectin for the first time. And, me and my colleague, we call it galectin, which mean, galactose, the sugar called galactose, galactose, galactose binding lectin or galectin. And, there are, today about 11,000 publications about galectins since we published that in 1992. Also, researched the structure of galectin in those days, and there's another article, a publication, that I that, from 1993. And over the years, I research galectin receptors extensively and how they bind, how we can block him block them with, with polysaccharide. Today, there are known, there are about 16 galectins are known. In the early days, we, I identified two of them, Galectin-3 and Galectin-1. There are books that, we, me and my colleagues created. One is the galectin first textbook, and the second one is by American Chemical Society, how to make a polysaccharide, not just for galectin, as a delivery mechanism and a treatment for a different disease. So what we did with the antagonist, in case of a antiviral, we discovered that we have a unique galectin makeup on different viruses. All of them contain galectin, but the one that interests the most were the one that I mentioned before, RSV, influenza, those respiratory viruses, and we took the COVID-19 as a case study, and we build the, against that, we build the molecule, mostly by NMR, nuclear magnetic resonance, and analyzing the structure and the binding to galectins. We came with a structure, a polysaccharide structure. It based on the mathematics, AI, and, we got to a, a molecule that we agreed that that's the best, I would call it, broad range molecule against different viruses, that more or less contain the galectins that we were interested in to block. We need to block all of them, which is some of them, exist in, groups on the surface of the virus. In this case, we took the COVID-19 as a case study because we had a lot of patients, and we did the phase I for safety and phase II. It's under FDA and under the Indian FDA. So it's a different name, CDSCO, but it's, basically the same FDA or same similar bodies in two countries. So we separately submit to those, to those two agencies, and we did phase II, a clinical trial, double-blind placebo control. And I want to show you the data. The data were published. The one who hear that for the first time will be very surprised to see the data, and the one who knows the company. Not many people know the company, but the data are extremely, very good. And look, in this case, it's remember, this is double-blind placebo control, and at day three, 88% of the patients at the PCR or the measurement of the virus in their, in them, were not detected. By day seven, the only where there were no detection of the viral infection. In this slide, I'm comparing to Paxlovid, the Pfizer's drug. It's we didn't compare it in a clinical trial, it's just we took the data from the literature, the published literature, and you can see that here, after 25 days, only 30 percent of the patient were out of a, I mean, viral, was, viral was not detected, and we are here at day three, four, five, and that's it. So the magnitude we published the data. It's published. You can read about that in the literature. And we're talking about just in the current antiviral, I would say, there are different numbers, but the magnitude of that, what you saw here is very high. We're talking about a total market of the antiviral estimate to be around $80 billion. So what we have here, what we develop, is a broad-range antiviral drug, which one of the features of this drug, it's... First of all, it's very safe, and we didn't have any adverse effect to date. It's made of a polysaccharide, and I will later, in a minute, I will explain how or actually we can do early, early commercialization by actually selling that without medical claim. So first of all, it made of a polysaccharide that was approved by the FDA, which has modified them. And secondly, since the galectin is conservative, we really mutation of the virus does not affect the viral antiviral activity, because the galectin receptor are conservative receptors, and they are not mutate so much over, I mean, this, they're all... Different viruses, they're all the same, different galectin, but they by themselves not mutate. They are essential for the infection. As you see, the efficacy is very high. You cannot get better than 100%, and, we can actually do in the future, we can show that we can have a prophylactic effect. You just take it in advance, and you don't get infected. So, just to, explain what it is, it's on the spike protein, a very unique position, where very important for the infection mechanism. And the galectin is sitting here and recognizing the polysaccharide on the host or what the cell that it's infected.... This technology is a major, in my opinion, and obviously, I can talk about what I'm presenting here, but it's the magnitude of that type of data, it's very high. This is the first time where we can actually design a polysaccharide for different viruses and treat them, not through the immune system, using the immune system, but treating them as a, so to speak, that's the anti in the parallel explanation, it's like antibiotics for viruses. So it's if you design in the early stage, antibiotics discovered, and then different antibiotics make different treat different bacteria. In this case, the polysaccharide can be designed by NMR studies in the lab, by AI, and based on the galectin on the surface of the different viruses, and then we design the polysaccharide based on the virus. In this case, we did a broad-range antiviral, and to confirm that, the data that I demonstrate in my previous slide, we did another phase II, a double blind placebo control, for different reason. Number one, the agency required to do that again, because we use, in the first trial, we use 10 tablets for each day, and now we did a dose response of up to four tablet only, and the data should come very soon. We are analyzing the data currently. If the data will be similar to the data in the first phase II double-blind placebo control, I estimate that we develop one of the best broad-range antiviral, and the future on this thing is bright, because we, for the first time, a mass production can be made and deal for people that even are not vaccinated around the world. Just why, why it's very exciting from my perspective and from our perspective, that in this case, you have a case study when a company in the middle of developing. We're talking about the carbohydrate, the moieties, or the carbohydrate drug type chemistry. So in this case, the company continued developing. This case, you can see a case when with the FDA, when the FDA approved the, in the milestone, they approve it as a, or let the company sell it, it's a nutraceutical type without a medical claim, although the same chemistry, and continue to develop to phase III to give a medical claim for specific virus. We develop our drug as a broad range, so we just need to go virus or group of virus by viruses, and then we will say, once we have it approved in phase III, we will say, "The drug works against influenza, and we may-- and the drug works against other COVID or other viruses." So that's the from a regulatory perspective. In general, the company doing other technologies, but what the second one, as I mentioned, is delivery. We deliver with polysaccharide oxygen, and the way we do it in early stroke, as you know, there's no treatment because you cannot distinguish between hemorrhagic and ischemia, and you need to take the person to the hospital to do MRI, and then you can treat them to dissolve the clot or treat the person with the thrombectomy or taking out the clot. Here, we are coming with the early stage, and what we did, we take erythrocyte or the red blood cells from camel. We are the only company in the world who's doing that. The reason for camel, because camel blood is very stable. We have an FDA-approved camel for that source of material. It's quite difficult, but we did it. It's a, it's a very nice situation. So we have a way, we take it from the camel, the specific erythrocyte, which is a very stable type of red blood cells, and out of it, we take the hemoglobin, and out of that, we take the heme. The heme is the part that connect the oxygen, and by taking the heme and put it on a polysaccharide, we create a molecule, which call it BXT-25, to deliver the oxygen. The heme is connecting the oxygen, oxygen, and the polysaccharide is support for the heme. As a consequence, we create a molecule which is 5,000 times in size less than red blood cells. It's stable in room temperature for years. Right now, we know that it's stable for 5 years. We're now testing. We believe it can be stable between 10 to 15 years. Right now, we're testing that, and you can keep it, obviously, as I said, in room temperature on the shelf. You can actually boil that, and nothing will happen because it's a polysaccharide and a heme. That's it. We call it universal oxygen carrier, and one of the question was how you detect the oxygen that we deliver. So, for that, we develop a device, that the device measure all the oxygen molecules that we deliver one by one, and we, the device detect it through the mitochondria in every single cell. It was approved by the FDA in clinical trial, and it was, and we have a designation of 510(k), which is approved for a measurement, and it's a surrogate marker, so to speak. So what it means, that when we will do the clinical trial, with that molecule, the BXT-25, and we deliver that into the patients, we can detect all the molecules of the oxygenation in the brain, and the ability to detect it is our ability to actually approve it with the functionality, and later, for each type of need. For example, ischemia, oxygenation of a tissue as a wellness or a hyperbaric. We can replace hyperbaric chamber, because we are not delivering oxygen to 5% like hyperbaric chamber do. We're delivering it similar to, red blood cells when you give whole blood. There are other, like, ischemia, anemia, wound healing. This is a very big potential for this molecule, but, we are now, entering clinical trial. In the future, once we have accumulate, we will accumulate more knowledge in the toxicity. We are in the process of finishing the toxicity testing, and will be in human as funding will be available. By the way, I want to mention when fund is available, we'll, I'll talk about that later, how the strategy will play out, from that perspective. The company is covered with a patent. We have a material patent. I'm talking about structure and use, and we talking to companies right now for the antiviral. Basically, the concept about the antiviral is to make the company in our management we are trying to for phase III we're trying to get a deal with a drug company or with a large marketing company, and we have two options. One is to generate revenue under the nutraceutical or selling that as a nutraceutical, and the same time, to have a company fund the phase III to go forward and get it approved and market it as a drug. I want to mention in our management, Avraham Mayevsky is the person behind the device. It's 60 years of research, and Kevin Mayo is my collaborator in University of Minnesota, which we do all the binding and the studies to design those polysaccharides and how they and their structure and the chemistry. It's basically, again, I want to reiterate, that this is a mathematics. It's polysaccharide, considered the most complex chemistry. It's the unknown, it's the future, and you can do a lot of things with them. It require AI, it require a structural analysis and the knowledge about the If you read our article, it describes all the process that we went through in the studies of those polysaccharide. As a company, we formed in 2017. There are 37 million shares in the float, only 2,100 shareholders. It's evaluate right now between 5 and 7, and that's my presentation for today. Great. Thank you very much, Dr. Platt. Very interesting presentation with a lot of information there. Just going through the programs, could you just elaborate on when the next clinical data will be coming out on the double blind, placebo-controlled trial, and when it will be published? ... The data right now are crunched by our CRO, Contract Research Organization. We will publish them as soon as they will be available to the public. My hope, I don't know the data yet. My hope, if the data will be similar to the previous double-blind placebo-controlled phase II, and this study, what we have now, it's a confirmatory study. It mean, it's supposed to confirm what we found in the first study. Sure. The second question, we did what you call dose response. On dose, the first study, we did 10 pills a day. Obviously, no one will take 10 pills, 10, 10 tablets a day. It's a chewable tablet. You take it, you take it, and that's it. There's a whole technology around the chewable tablet, but we developed that. It's by itself. The second phase II supposed to teach us about doses. What will it require if what one pill, two pill, three pill, four pills a day, it requires some patience having the right patients in. We complete everything nicely, and we're waiting for the data. If the result will be similar or even close to what we did in the first time, it's a sea change in antiviral infection treatment. It's a sea change. It will go to... Since it's so safe, everybody can take it, and it's so quick. And we're talking about, you know, getting out of symptoms in the first study after hours. It will be a major technology in terms of, I anticipate, major demand. And part of the question that we are receiving now from a potential collaborator: Can you do 10 billion tablets? Can you do 20 billion tablets? What is your capacity on the supply chain? And we need to answer all these questions, and we are working on that, diligently. So, answer the question, I'm waiting for that phase II, and then the phase III is obviously, it's a broad range. We will take all comers. We'll start maybe with influenza, and then, because for us, the COVID was a case study. We start with influenza, RSV, rhinovirus, rhinovirus, and, we have a couple of viruses. It's a broad, broad range. We'll go one by one or all together, and we'll finish the phase III with a, with a claim, medical claim. Okay. Well, yes, one of the questions I was going to ask was about phase III, which you just answered. So, just, could you just sum up in a sentence or two about what's so unique about this approach and just the core impact of the technology? Right. Concurrently, every antiviral today are doing, are dealing with the immune system. We, by blocking the immune, the replication of the virus in the cell, or by dealing with the immune system to go after the virus, that's the current technology. In vaccine, it's, activating the immune system, and in a treatment, you'd inject some antibodies, something to kill the virus or the cell that are infected. We are a, we are a different animal in terms of what we do, we're going after the viral, viral inf- virus itself and blocking the surface or the Galectin on the surface. It's a completely total approach, different than as any immune modulator or any, other methodology, including a replication. And I, I'm sure that many-- first of all, Glycovirology almost does not exist as a science. It's just a name. We are the first one of the first companies in this field, and it require a structural biology knowledge, a lot of software, analysis of chemistry, and recognition of binding, which is not really virology. It's more, mostly it's about structural chemistry. I'm a chemist in my background. I was a computational, I'm still a computational scientist, and I'm in polysaccharide. So my view is that based on the data that we have, I think that we have the solution for quick treatment and prophylaxis in a scale that unimaginable. I see the future, and I'm not saying that vaccine is not supposed to be a way or treatment. They will stay, and it will take years for scientists to follow and to understand what we see here, but one drug like that on the market can save many people lives. Great. Thank you. Very interesting presentation. Yeah. Look forward to following all of these events as they're announced over the next year. Thank you very much for your presentation. Thank you.